CPA
ZURA icon

Capital Performance Advisors’s Zura Bio ZURA Stock Holding History

Capital Performance Advisors’s Portfolio ZURA Stock Details ZURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-75
Closed -$305 – 2771
2024
Q3 		$305 Buy
+75
New +$280 ﹤0.01% 2458

Other funds holding ZURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Capital Performance Advisors's ZURA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Zura Bio (ZURA) in Q4 2024, closing a stake of 75 shares — an estimated $305 sold.

Capital Performance Advisors first reported a position in ZURA in Q3 2024 and held it in 1 quarter. The position peaked at $305 in Q3 2024. 87 funds tracked by Wall St. Rank hold ZURA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Zura Bio position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 75 Zura Bio shares in Q4 2024, an estimated $305.
  • Capital Performance Advisors first reported a position in Zura Bio in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Zura Bio position peaked at $305 in Q3 2024.
  • 87 funds tracked by Wall St. Rank held Zura Bio as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.